Management of severe postpartum hemorrhage with a prostaglandin F2 alpha analogue.
Presented is a three-year study using a 15-methyl analogue of prostaglandin F2 alpha, in the management of severe postpartum hemorrhage due to uterine atony in patients who were unresponsive to conventional therapies. Fifty-four patients were entered into the study, but 51 were analyzed for efficacy. Successful control of postpartum hemorrhage occurred in 86%. Of the seven in whom therapy failed and who subsequently required surgical therapy, four had chorioamnionitis. Six subjects had intramyometrial injection of the agent, with dramatic results in five. Mild transient side effects occurred in less than 10% of subjects.
D000328:Adult; D002260:Carboprost / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006473:Postpartum Hemorrhage / Q000188:drug therapy*; D011247:Pregnancy; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*
D011461:Prostaglandins F, Synthetic; D002260:Carboprost